CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (81,316)	$ (86,386)
Adjustments to reconcile net loss to net cash used in operating activities:
Early termination of operating lease	(454)
Stock-based compensation expense	10,808	12,082
Non-cash interest expense	1,361	1,256
Depreciation and amortization	789	1,062
Changes in operating assets and liabilities:
Receivables	24,301	(30,057)
Prepaid expenses and other	1,769	5,740
OMIDRIA contract royalty asset	(6,815)
Accounts payable and accrued expense	(11,544)	4,796
Net cash used in operating activities	(61,101)	(91,507)
Investing activities:
Purchases of investments	(103,573)	(5)
Proceeds from the sale and maturities of investments	84,600	81,500
Purchases of property and equipment	(100)	(203)
Net cash provided by (used in) investing activities	(19,073)	81,292
Financing activities:
Proceeds from OMIDRIA liability for future royalties	125,000
Proceeds upon exercise of stock options and warrants	414	8,076
Payments on finance lease obligations	(515)	(706)
At the market offering costs		(241)
Net cash provided by financing activities	124,899	7,129
Net decrease in cash and cash equivalents	44,725	(3,086)
Cash and cash equivalents at beginning of period	100,808	10,501
Cash and cash equivalents at end of period	145,533	7,415
Supplemental cash flow information
Cash paid for interest	13,437	14,889
Property acquired under finance lease	$ 806	$ 139